Akero Therapeutics, Inc.
AKRO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AKRO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Sep 30, 2025.
Tracking 6 clinical trials for Akero Therapeutics, Inc..
Run Akero Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Akero Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
31.9 months
D/E 0.05 · 2% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Governance
Frequently asked questions
Who is the CEO of Akero Therapeutics, Inc.?
Chief Executive Officer is the chief executive officer of Akero Therapeutics, Inc. (AKRO).
What therapeutic areas does Akero Therapeutics, Inc. focus on?
Akero Therapeutics, Inc. develops therapies across Infectious Disease, Metabolic, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.